Mirum Pharmaceuticals Valuation
| MIRM Stock | USD 103.10 1.09 1.07% |
At this time, the firm appears to be undervalued. Mirum Pharmaceuticals secures a last-minute Real Value of $112.73 per share. The latest price of the firm is $103.1. Our model forecasts the value of Mirum Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 6.12 B, profit margin of (0.09) %, and Return On Equity of -0.16 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Mirum Pharmaceuticals' valuation include:
Price Book 21.1474 | Enterprise Value | Enterprise Value Ebitda (8.85) | Price Sales 13.0854 | Forward PE 39.6825 |
Undervalued
Today
Please note that Mirum Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Mirum Pharmaceuticals is based on 3 months time horizon. Increasing Mirum Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Mirum stock is determined by what a typical buyer is willing to pay for full or partial control of Mirum Pharmaceuticals. Since Mirum Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mirum Stock. However, Mirum Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 103.1 | Real 112.73 | Target 114.7 | Hype 102.74 |
The intrinsic value of Mirum Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mirum Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mirum Pharmaceuticals helps investors to forecast how Mirum stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mirum Pharmaceuticals more accurately as focusing exclusively on Mirum Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Mirum Pharmaceuticals' intrinsic value based on its ongoing forecasts of Mirum Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Mirum Pharmaceuticals' closest peers.
Mirum Pharmaceuticals Cash |
|
Mirum Pharmaceuticals Total Value Analysis
Mirum Pharmaceuticals is now projected to have valuation of 6.12 B with market capitalization of 6.17 B, debt of 317.76 M, and cash on hands of 124.95 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Mirum Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.12 B | 6.17 B | 317.76 M | 124.95 M |
Mirum Pharmaceuticals Investor Information
About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.84. Mirum Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Mirum Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Mirum Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Mirum Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Mirum Pharmaceuticals has an asset utilization ratio of 50.23 percent. This suggests that the Company is making $0.5 for each dollar of assets. An increasing asset utilization means that Mirum Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Mirum Pharmaceuticals Profitability Analysis
Based on Mirum Pharmaceuticals' profitability indicators, Mirum Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Mirum Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 2018-09-30 | Previous Quarter -5.9 M | Current Value 2.9 M | Quarterly Volatility 22.3 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.89 | 0.87 |
|
|
For Mirum Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Mirum Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Mirum Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Mirum Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Mirum Pharmaceuticals over time as well as its relative position and ranking within its peers.
Mirum Pharmaceuticals Earnings per Share Projection vs Actual
By analyzing Mirum Pharmaceuticals' earnings estimates, investors can diagnose different trends across Mirum Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Mirum Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Mirum Pharmaceuticals Ownership Allocation
The majority of Mirum Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mirum Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mirum Pharmaceuticals. Please pay attention to any change in the institutional holdings of Mirum Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Mirum Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 336.89 M. Net Loss for the year was (87.94 M) with profit before overhead, payroll, taxes, and interest of 377.04 M.About Mirum Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Mirum Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Mirum Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Mirum Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Mirum Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mirum Pharmaceuticals. We calculate exposure to Mirum Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mirum Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 293.5 M | 308.2 M | |
| Pretax Profit Margin | (0.23) | (0.24) | |
| Operating Profit Margin | (0.23) | (0.25) | |
| Net Loss | (0.23) | (0.25) | |
| Gross Profit Margin | 0.87 | 0.89 |
Mirum Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Mirum Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 47.5 M | |
| Forward Price Earnings | 39.6825 |
Mirum Pharmaceuticals Current Valuation Indicators
Mirum Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Mirum Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Mirum Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Mirum Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Mirum Pharmaceuticals' worth.When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Will Biotechnology sector continue expanding? Could Mirum diversify its offerings? Factors like these will boost the valuation of Mirum Pharmaceuticals. Expected growth trajectory for Mirum significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mirum Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.84) | Revenue Per Share | Quarterly Revenue Growth 0.472 | Return On Assets | Return On Equity |
Understanding Mirum Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Mirum's accounting equity. The concept of intrinsic value - what Mirum Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Mirum Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Mirum Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mirum Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Mirum Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.